‍

PRIME-ROSE was represented at the ASCO Annual Meeting May 29 – June 2, 2026, contributing to ongoing international discussions on precision oncology and strengthening collaboration with global initiatives such as TAPUR and CAPTUR.

At this year’s ASCO Annual Meeting, the PRIME-ROSE project actively engaged with the international cancer research community, continuing its mission to advance personalised cancer care through data-driven approaches and collaborative clinical research.

A key highlight of the participation was the presentation of a PRIME-ROSE poster, showcasing the project’s progress in implementing innovative trial methodologies and data integration approaches to support more effective and equitable cancer treatment strategies across Europe.

In addition to the scientific programme, PRIME-ROSE representatives participated in dedicated discussions with partners from the TAPUR (Targeted Agent andProfiling Utilization Registry) and CAPTUR (Canadian Profiling and UtilizationRegistry) studies. These interactions build on last year’s exchanges and further strengthen transatlantic collaboration on registry-based clinica lresearch and real-world evidence generation.

Thecontinued dialogue between PRIME-ROSE, TAPUR and CAPTUR reflects a sharedcommitment to:

• accelerating access to targeted therapies
• improving the use of molecular profiling in clinical decision-making
• harmonising data collection and analysis across international initiatives

‍

By fostering collaboration between European and North American initiatives, PRIME-ROSE contributes to the global effort to advance personalised cancer care and to ensure that patients benefit from the latest scientific and clinical developments.

‍